Kyntra Bio, Inc. (KYNB)

Kyntra Bio Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	50.64	47.87	50.48	81.55	155.7	171.22
Short-Term Investments	40.67	41.11	-	121.9	266.31	233.97
Cash & Short-Term Investments	91.32	88.98	50.48	203.45	422.01	405.19
Cash Growth	290.80%	76.26%	-75.19%	-51.79%	4.15%	-40.98%
Accounts Receivable	0.35	0.22	0.48	5.12	16.3	25.4
Other Receivables	-	4	28.5	28.5	-	-
Receivables	0.35	4.22	28.98	33.62	16.3	25.4
Inventory	3.38	3.74	3.16	17.17	40.44	31.02
Prepaid Expenses	0.94	1.02	1.9	4.86	9.73	7.38
Other Current Assets	0.83	1.12	111.99	72.46	4.35	5.07
Total Current Assets	96.83	99.07	196.51	331.56	492.83	474.06
Property, Plant & Equipment	-	-	-	69.86	100.93	120.15
Long-Term Investments	4.01	20.16	-	-	9.41	171.62
Other Long-Term Assets	0.24	0.36	18.02	22.11	6.92	7.99
Total Assets	101.08	119.59	214.53	423.53	610.09	773.82

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	7.51	3.75	5.06	15.78	30.76	26.1
Accrued Expenses	15.57	9.51	13.02	40.39	130.19	121.62
Current Portion of Leases	-	-	-	12.65	10.33	10.96
Current Unearned Revenue	5.63	6.65	27.75	18.39	12.74	19.03
Other Current Liabilities	7.33	9.34	87.48	130.46	89.55	47.79
Total Current Liabilities	36.04	29.24	133.31	217.67	273.56	225.5
Long-Term Debt	-	19.56	90.1	89.7	16.92	17.61
Long-Term Leases	-	-	-	65.14	79.73	88.78
Long-Term Unearned Revenue	73.12	66.24	173.57	208.97	235.06	186.8
Other Long-Term Liabilities	0.07	0.08	1.18	4.26	6.3	26.02
Total Liabilities	109.22	115.12	398.16	585.73	611.57	544.71

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.04	1.01	1.01	0.99	0.94	0.93
Additional Paid-In Capital	1,680	1,677	1,669	1,644	1,541	1,476
Retained Earnings	-1,709	-1,706	-1,889	-1,842	-1,558	-1,264
Comprehensive Income & Other	-1.19	-2.18	-5.73	-6.88	-5.72	-4.16
Total Common Equity	-30.14	-30.04	-225.6	-204.17	-21.45	209.15
Minority Interest	22	34.51	41.97	41.97	19.97	19.97
Shareholders' Equity	-8.14	4.48	-183.64	-162.2	-1.48	229.11
Total Liabilities & Equity	101.08	119.59	214.53	423.53	610.09	773.82

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	-	19.56	90.1	167.48	106.98	117.35
Net Cash (Debt)	91.32	69.42	-39.62	35.97	315.03	287.84
Net Cash Growth	-	-	-	-88.58%	9.45%	-54.17%
Net Cash Per Share	22.56	17.17	-9.90	9.24	84.16	77.92
Filing Date Shares Outstanding	4.05	4.05	4.04	3.95	3.77	3.72
Total Common Shares Outstanding	4.05	4.05	4.04	3.95	3.77	3.72
Working Capital	60.79	69.83	63.2	113.89	219.26	248.56
Book Value Per Share	-7.44	-7.42	-55.89	-51.68	-5.69	56.29
Tangible Book Value	-30.14	-30.04	-225.6	-204.17	-21.45	209.15
Tangible Book Value Per Share	-7.44	-7.42	-55.89	-51.68	-5.69	56.29
Machinery	-	-	-	32.82	46.5	43.51
Construction In Progress	-	-	-	-	0.2	2.42
Leasehold Improvements	-	-	-	84.92	102.58	103.35

Data Source: S&P Global Market Intelligence Last updated: May 12, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 19, 2026

Data Sources Report a data error